ClinicalTrials.gg
Not yet recruitingNCT07938463Updated Nov 16, 2026

Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC

A Phase 1 interventional study of TNG462 vopimetostat and Lorlatinib in ALK Positive Non-small Cell Lung Cancer, sponsored by Dana-Farber Cancer Institute. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Dana-Farber Cancer Institute · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute — 4 open to participants now, 7 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Dana-Farber Cancer Institute.

Planned enrollment
9th of 19
30 · median 30
Started
2027
the only one that year
Phase 1
2 of 20
1 open now
Registered
20th of 20
by date

Among the 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute, this one is the 9th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 1, and was the 20th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. The study is being conducted under IND 183798 and plans to enroll 30 participants.

Read the detailed description

This study evaluates a treatment regimen combining TNG462 and lorlatinib, both administered once daily per the consent study plan. Baseline assessments are performed before registration, with protocol-specified on-treatment visits during Cycle 1, Cycle 2, and subsequent cycles. Scheduled evaluations include physical examinations, vital signs, weight, performance status, laboratory testing, ECGs, adverse event review, and tumor measurements. Tumor imaging is repeated every 2 cycles for the first 6 months, then every 3 cycles thereafter. The consent form also describes optional tumor biopsies and optional plasma/serum collections for research.

For the Phase I portion, the protocol states that a BF-BOIN dose-escalation and backfilling design will be used, with no formal stratification factors applied to dose-escalation decisions.

03

Conditions studied

  • ALK Positive Non-small Cell Lung Cancer

Keywords

  • Non-Small Cell Lung Cancer (NSCLC)
  • ALK-positive NSCLC following progression on prior TKI therapy
  • MTAP-deleted, ALK-rearranged NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • or cytologically confirmed NSCLC harboring an ALK rearrangement, documented by an FDA/EMA-approved or validated local test.
  • Confirmed MTAP loss, demonstrated by immunohistochemistry (IHC) as complete loss in the presence of a positive internal control, or homozygous deletion by next-generation sequencing (NGS) in a CLIA-/ISO-accredited laboratory. The Sponsor-Investigator will review molecular testing to confirm eligibility (central reading of the IHC sample and/or repeat MTAP staining on ; check of the NGS report). Cases with heterogenous MTAP loss in IHC defined as MTAP loss in at least 80% of the tumor cells but less than 100%, may be included with the permission of the Sponsor-Investigator and after central revision of the slides.
  • Radiographic disease progression after at least one or more ALK TKIs, including prior lorlatinib therapy. Prior chemotherapy and prior neladalkib (NVL-655) are allowed
  • At least one measurable extracranial lesion according to v1.1.
  • performance status 0-1 (Appendix A). ECOG performance status 2 may be allowed with the permission of the Sponsor-Investigator
  • Adequate organ and marrow function, defined as:

    • ≥ 1.5 × 10⁹/L
    • ≥ 75 × 10⁹/L, without platelet transfusion within 7 days prior to screening hematology assessment
    • > 8.5 g/dL without transfusion within 14 days prior to screening hematology assessment
    • /ALT ≤ 2.5 × (≤ 5 × ULN with documented liver )
    • Total ≤ 1.5 × ULN
    • ≥ 45 mL/min
  • Stable, previously treated permitted if neurologically stable ≥ 2 weeks and on ≤ 10 mg prednisone equivalent. Untreated CNS metastases may be permitted with PI approval if: lesions are asymptomatic, ≤5 mm in size, no radiologic evidence of surrounding edema, and no current or anticipated need for .
  • ≥ 12 weeks.
  • Ability to swallow oral medication. TNG 462 tablets may be crushed and administered via NG-G tube if necessary, with written approval from Principal Investigator. Lorlatinib may not be crushed.
  • Written obtained prior to study procedures.
  • Participants must understand, sign and date the written informed consent form prior to any protocol-specific procedures performed. Participants should be able and willing to comply with study visits and procedures as per protocol

Exclusion criteria

Exclusion Criteria:

  • 3.2.1 Prior treatment with a PRMT5 inhibitor, MAT2A inhibitor, or any agent targeting the same pathway.

3.2.2 Prior treatment with lorlatinib resulting in discontinuation due to ≥ Grade 3 toxicity or with unresolved ≥ Grade 2 neurocognitive, pulmonary, or psychiatric adverse events at screening.

3.2.3 Ongoing or unresolved toxicity > Grade 1 from previous anticancer therapy (per v5.0), except for the following: alopecia, endocrinopathies controlled by replacement therapy, or other protocol-allowed persistent Grade 2 toxicities (e.g., neuropathy) that, in the investigator's judgment, do not pose an unacceptable safety risk.

3.2.4 Major surgery within 4 weeks before first dose or incomplete recovery from surgery

3.2.5 Radiotherapy within 2 weeks before C1D1 (≤ 1 week for palliative RT ≤ 2 Gy/fraction); prior cranial RT permitted if completed ≥ 2 weeks before C1D1 and participant neurologically stable.

3.2.6 Concomitant use of strong or moderate inhibitors or inducers, CYP3A or P-gp substrates with a narrow therapeutic index (e.g., digoxin, cyclosporine), or OATP1B3 substrates with a narrow therapeutic index (e.g. rosuvastatin, methotrexate, sirolimus), that cannot be discontinued or replaced.

3.2.7 Use of medications known to prolong > 480 ms that cannot be safely discontinued.

  • or spinal cord compression unless treated, clinically stable ≥ 4 weeks, and off ≥ 14 days.
  • History of seizure disorder requiring enzyme-inducing antiepileptic drugs that cannot be substituted.
  • Baseline QTc > 480 ms (Fridericia), PR > 220 ms, atrioventricular (AV) block, or uncontrolled arrhythmia.
  • History of myocardial infarction, unstable angina, coronary revascularization, stroke, or (TIA) within 6 months before C1D1.
  • Symptomatic congestive heart failure ( ≥ Class II) or uncontrolled hypertension despite optimal medical therapy.
  • Interstitial lung disease, organizing pneumonia, or drug-induced pneumonitis, including prior lorlatinib-related pneumonitis, unless completely resolved.
  • Known -positive or -positive infection with detectable viral load. Participant on suppressive antiviral therapy with undetectable viremia are eligible.
  • infection with CD4 \< 200/μL or on antiretrovirals that are strong CYP3A modulators.
  • Active uncontrolled infection requiring intravenous therapy within 7 days before C1D1.
  • Clinically significant gastrointestinal disorder that may affect absorption of oral medications (e.g., malabsorption syndrome, chronic diarrhea, short-bowel syndrome).
  • Uncontrolled hyperlipidemia defined as fasting total cholesterol > 300 mg/dL or triglycerides > 300 mg/dL despite medical management.
  • Clinically significant neurocognitive disorder, mood alteration, or psychiatric illness (including major depression or psychosis) that, in the investigator's judgment, could be exacerbated by lorlatinib or impair adherence.
  • Any other active within 2 years prior to enrollment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, early-stage prostate cancer undergoing active surveillance, curatively treated thyroid cancer, early stage breast cancer or DCIS, or any in situ cancers that have been treated with curative intent.
  • Pregnancy or breastfeeding. Women of must have a negative serum pregnancy test within 7 days before first dose and agree to use two highly effective methods during treatment and for ≥ 6 months after the last dose. Male participants must use effective contraception for ≥ 3 months after the last dose.
  • Known to TNG462, lorlatinib, or any of their .
  • Has any of the following: prior history of drug-induced or toxic retinopathy, or optic neuropathy; uncontrolled glaucoma; pre-existing macular degeneration; ongoing Grade ≥3 retinopathy, optic neuropathy, or optic neuritis; or any other known active retinal pathology.
  • Any condition (medical, psychiatric, social, or laboratory abnormality) that, in the opinion of the investigator, may confound study results, increase risk, or interfere with study compliance.
  • Participants who, in the investigator's or Sponsor-Investigator's judgment, are unable to comply with protocol requirements or whose participation would not be in their best interest may be excluded.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    TNG462 plus Lorlatinib

    Participants receive TNG462 once daily and lorlatinib once daily according to the study treatment plan and study calendar.

    Drug: TNG462 vopimetostat · Drug: Lorlatinib

Interventions

  • DrugTNG462 vopimetostat

    Investigational drug Supplier/manufacturer: Tango Therapeutics

    Also known as: vopimetostat

  • Source/manufacturer: Commercial supply / Pfizer

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience Dose-Limiting Toxicity (DLT)

    A DLT is defined as a treatment-emergent adverse event occurring during Cycle 1 that is considered at least possibly related to TNG462, lorlatinib, or the combination and is not clearly attributable to underlying disease, intercurrent illness, or concomitant medications. DLTs include Grade ≥3 non-hematologic toxicities with specified exceptions for transient or manageable events; clinically significant hepatic, pulmonary, pancreatic, cardiac, ECG, CNS, or neurocognitive toxicities; Grade 4 hematologic toxicities; Grade ≥3 febrile neutropenia; Grade ≥3 thrombocytopenia with clinically significant bleeding; prolonged treatment-related hematologic toxicity requiring interruption of both study drugs for \>14 consecutive days; any toxicity resulting in permanent discontinuation of both study drugs during Cycle 1 due to safety concerns; and any death at least possibly related to study treatment during the DLT assessment period.

    Time frame: Up to 28 days.

  2. Maximum Tolerated Dose (MTD) of TNG462

    The study uses a Backfill Bayesian Optimal Interval (BF-BOIN) design to determine the MTD of TNG462. TNG462 will start at 200 mg QD and may be escalated to 250 mg QD at the optional Dose Level 3 if Dose Level 2 is tolerated, at the discretion of the Sponsor-Investigator.

    Time frame: Up to 28 days.

  3. MTD of Lorlatinib

    The study uses a BF-BOIN design to determine the MTD of Lorlatinib. Lorlatinib will start at 50 mg QD and may be escalated to 75 mg QD at Dose Level 2 if Dose Level 1 is tolerated. Lorlatinib will remain at 75 mg QD at the optional Dose Level 3.

    Time frame: Up to 28 days.

  4. Recommended Phase II Dose (RP2D) of TNG462 in Combination with Lorlatinib

    The study uses a BF-BOIN design to determine the MTD. The RP2D is selected from among acceptable dose levels at or below the MTD based on the totality of safety, tolerability, pharmacokinetic, and preliminary antitumor activity data obtained during Phase I.

    Time frame: Up to 28 days.

Secondary outcomes

  1. Objective response rate (ORR)

    The study uses a BF-BOIN design to determine the MTD. The RP2D is selected from among acceptable dose levels at or below the MTD based on the totality of safety, tolerability, pharmacokinetic, and preliminary antitumor activity data obtained during Phase I. ORR is defined as the proportion of patients achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

    Time frame: Tumor measurements are repeated every 2 cycles for the first 6 months and every 3 cycles thereafter.

  2. Duration of Overall Response (DOR)

    DOR based on Kaplan-Meier method is defined as the time from the first documented CR or PR until documented disease progression or death from any cause, whichever occurs first. Participants without disease progression or death will be censored at the date of their last disease evaluation.

    Time frame: From date of first documented CR/PR until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  3. Median progression-free survival (PFS)

    PFS based on Kaplan-Meier method is defined as the time from registration to progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.

    Time frame: From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  4. PFS Rate at 6 Months (PFS6)

    PFS6 rate is defined as the proportion of evaluable participants who are alive and free of documented disease progression at 6 months after registration. articipants with documented disease progression or death from any cause before 6 months are considered non-responders. Participants who withdraw, are lost to follow-up, or lack adequate disease assessment before 6 months will be considered non-evaluable. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.

    Time frame: Up to 6 months.

  5. Median Time to Treatment Failure (TTF)

    TTF based on the Kaplan-Meier method is defined as the time from registration to documented disease progression, death from any cause, permanent discontinuation of protocol therapy for toxicity or any other reason, or initiation of new systemic anticancer therapy, whichever occurs first. Participants who remain on protocol therapy without any of these events is censored at the date of their last protocol treatment administration.

    Time frame: From date of registration until the date of first documented progression or date of death from any cause or permanent discontinuation of protocol therapy, or initiation of new cancer therapy, whichever came first, assessed up to 24 months

  6. Median Overall Survival (OS)

    OS based on Kaplan-Meier method is defined as the time from treatment initiation until death due to any cause; participants who are alive at the time of analysis will be censored at the time of their last follow up.

    Time frame: From date of treatment initiation until the date of death from any cause, assessed up to 24 months

  7. Central Nervous System (CNS)-Specific PFS

    CNS-specific PFS based on Kaplan-Meier method is defined as the time from registration to the first documented intracranial disease progression or death from any cause, whichever occurs first. Intracranial progression is defined as progression of existing CNS lesions or the appearance of new CNS lesions according to RECIST v1.1 applied to CNS disease, as assessed by the investigator using protocol-mandated brain MRI. Participants without an event will be censored at the date of their last adequate CNS imaging assessment. Participants with extracranial-only progression will be censored at the date of their last CNS assessment.

    Time frame: From date of registration until the date of first documented intracranial progression or date of death from any cause, whichever came first, assessed up to 24 months

  8. Trough Concentrations of TNG462 and Lorlatinib

    Trough concentrations are defined as the measured plasma concentrations of TNG462 and lorlatinib.

    Time frame: At day 22.

  9. Central Nervous System (CNS) Adverse Event Rate

    CNS-AE Rate is defined as the proportion of participants who experience a CNS adverse event. AEs are graded based on CTCAE v5.0.

    Time frame: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

  10. Hypercholesterolemia Rate

    Hypercholesterolemia rate is defined as the proportion of participants who experience hypercholesterolemia. AEs are graded based on CTCAE v5.0.

    Time frame: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

  11. Hypertriglyceridemia Rate

    Hypertriglyceridemia rate is defined as the proportion of participants who experience hypertriglyceridemia. AEs are graded based on CTCAE v5.0.

    Time frame: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

  12. Hepatotoxicity Rate

    Hepatotoxicity rate is defined as the proportion of participants who experience hepatotoxicity. AEs are graded based on CTCAE v5.0.

    Time frame: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

  13. Interstitial Lung Disease or Pneumonitis Rate

    Interstitial lung disease or pneumonitis rate is defined as the proportion of participants who experience interstitial lung disease or pneumonitis. AEs are graded based on CTCAE v5.0.

    Time frame: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

  14. Hematologic Toxicity Rate

    Hematologic toxicity rate is defined as the proportion of participants who experience a hematologic toxicity. AEs are graded based on CTCAE v5.0.

    Time frame: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months

  15. Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Physical Functioning Scores

    Physical functioning is assessed using EORTC QLQ-C30. The physical functioning scale consists of 5 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better physical functioning.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  16. Change from Baseline in EORTC QLQ-C30 Role Functioning Scores

    Role functioning is assessed using the EORTC QLQ-C30. The role functioning scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better role functioning.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  17. Change from Baseline in EORTC QLQ-C30 Emotional Functioning Scores

    Emotional functioning is assessed using the EORTC QLQ-C30. The emotional functioning scale consists of 4 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better emotional functioning.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  18. Change from Baseline in EORTC QLQ-C30 Cognitive Functioning Scores

    Cognitive functioning is assessed using the EORTC QLQ-C30. The cognitive functioning scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better cognitive functioning.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  19. Change from Baseline in EORTC QLQ-C30 Social Functioning Scores

    Social functioning is assessed using the EORTC QLQ-C30. The social functioning scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better social functioning.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  20. Change from Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Scores (QoL)

    Global health status/QoL is assessed using the EORTC QLQ-C30. The global health status/QoL scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better global health status and quality of life.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  21. Change from Baseline in EORTC QLQ-C30 Fatigue Scores

    Fatigue is assessed using the EORTC QLQ-C30. The fatigue scale consists of 3 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater fatigue.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  22. Change from Baseline in EORTC QLQ-C30 Nausea and Vomiting Scores

    Nausea and vomiting are assessed using the EORTC QLQ-C30. The nausea and vomiting scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater nausea and vomiting.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  23. Change from Baseline in EORTC QLQ-C30 Pain Scores

    Pain is assessed using the EORTC QLQ-C30. The pain scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater pain.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  24. Change from Baseline in EORTC QLQ-C30 Dyspnea Score

    Dyspnea is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater dyspnea.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  25. Change from Baseline in EORTC QLQ-C30 Insomnia Score

    Insomnia is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater insomnia.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  26. Change from Baseline in EORTC QLQ-C30 Appetite Loss Score

    Appetite loss is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater appetite loss.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  27. Change from Baseline in EORTC QLQ-C30 Constipation Score

    Constipation is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater constipation.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  28. Change from Baseline in EORTC QLQ-C30 Diarrhea Score

    Diarrhea is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater diarrhea.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  29. Change from Baseline in EORTC QLQ-C30 Financial Difficulties Score

    Financial difficulties are assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater financial difficulties.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

  30. Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) Scores

    The EORTC QLQ-LC13 is a 13-item lung cancer-specific questionnaire comprising symptom scales and single items. Each scale and item score is transformed to a range of 0 to 100, with higher scores indicating greater symptom burden.

    Time frame: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: DFCI- Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Nov 2027, 7 months later.

Of 226 non-industry phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's planned 7 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 16, 2026
StartEst.
Apr 30, 2027
Primary completionEst.
Nov 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938463
Collaborators
Tango Therapeutics, Inc., ALK Positive / ALK Positive Patients Association
Responsible party
Alice Shaw, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Nov 16, 2026
Start date
Apr 30, 2027 (estimated)
Primary completion
Nov 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Alice Shaw, MD, PhD
Contact
alice_shaw@dfci.harvard.edu
617-632-5301
Alice Shaw, MD, PhD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion